Overview
Chonluten is a synthetic tetrapeptide (Ala-Glu-Asp-Leu, abbreviated AEDL) developed within Vladimir Khavinson's peptide bioregulator research programme at the St. Petersburg Institute of Bioregulation and Gerontology. It is classified as a "bronchial epithelium bioregulator" — part of a family of very short peptides designed by Khavinson's group to mimic naturally occurring tissue-specific regulatory peptides, on the theory that respiratory tissue produces its own short peptide signals that decline with age and with chronic irritant exposure such as smoking.
It is important to state plainly what the evidence base for Chonluten actually looks like: almost all published research originates from Khavinson's own laboratories or closely affiliated Russian institutions, published largely in Russian-language journals or their English-language sister publications (e.g.
Bulletin of Experimental Biology and Medicine,
Advances in Gerontology,
Neuroscience and Behavioral Physiology). There is no independent Western replication, no registered Western clinical trial, and no regulatory approval for Chonluten as a medicine in the EU, UK, or Ireland. Readers should treat the findings below as a specific, narrow research literature — not as consensus science — and weigh that context heavily.
Within that literature, Chonluten is studied mainly in aged and smoking-model rodent studies, and in bronchial/lung epithelial tissue and cell culture models, for effects on bronchial epithelium function, respiratory tissue markers, and chronic-bronchitis-adjacent research contexts published within Russian gerontology and pulmonology-adjacent sources. This guide is for educational and research purposes only. Not medical advice.
Clinical & Research Status
| Evidence Type |
Status |
| Human RCT (Western) |
✗ |
| Human RCT (Russian, small-scale) |
✔ (limited) |
| Animal Studies |
✔ |
| In Vitro |
✔ |
| Regulatory Approval (Ireland/EU) |
✗ |
Mechanism of Action
Chonluten's proposed mechanism is not receptor-based in the way conventional pharmaceuticals are described. Khavinson's peptide bioregulator theory proposes that very short peptides (2-4 amino acids) can interact directly with gene promoter regions or chromatin, modulating transcription of genes relevant to the tissue the peptide is derived from — in this case, bronchial and lung epithelial tissue. This is a substantially different and far less mechanistically established framework than classical receptor pharmacology.
Preclinical papers from the Khavinson group report that Chonluten has been observed to support normalisation of bronchial epithelial cell markers and a reported reduction in markers of oxidative and inflammatory stress in lung tissue of aged and smoking-exposed animal models. Proposed downstream effects include modulation of gene expression linked to bronchial epithelium regeneration and mucous membrane function. These mechanisms are reported almost exclusively by the originating research group and have not been independently confirmed through Western peer-reviewed replication.
Research Areas & Reported Effects
Bronchial Epithelium Function
The bulk of Chonluten-specific research relates to bronchial epithelial cell markers and tissue structure in aged rodent and in vitro lung tissue models, given its classification as a bronchial-tissue bioregulator. Reported findings describe has been observed to support in epithelial cell regeneration markers and reduced structural degeneration in bronchial tissue following Chonluten administration.
Smoking-Related Lung Tissue Models
Several Khavinson-affiliated papers report reduced markers of smoking-induced oxidative and inflammatory damage in bronchial and lung tissue of animal models exposed to cigarette smoke or comparable irritants, presented as evidence for a respiratory-tissue-protective research profile in this specific context.
Chronic Bronchitis-Adjacent Research Contexts
Chonluten has been referenced within Russian gerontology and respiratory-research literature discussing chronic bronchitis-adjacent degenerative processes in ageing and smoke-exposed lung tissue, though this remains a narrow and preliminary body of research rather than dedicated chronic bronchitis clinical trial data. Reported outcomes in this context describe has been observed to support in bronchial tissue markers relative to untreated comparison groups.
Research Data Summary
| Study / Model |
Reported Effect |
| Aged Rat Bronchial Tissue Model (Khavinson et al.) |
Reported support for bronchial epithelial cell regeneration markers relative to untreated aged controls. |
| Smoking-Exposure Rodent Model |
Reported reduction in markers of oxidative and inflammatory damage in lung/bronchial tissue. |
| In Vitro Bronchial Epithelial Cell Culture |
Reported normalisation of epithelial cell function markers under experimental conditions. |
| Gene Expression Analysis (Bronchial Tissue) |
Reported modulation of gene expression markers linked to bronchial epithelium regeneration. |
Stack Combinations Studied
- Chonluten + Vilon → Research rationale: Explored in Russian gerontology literature as a combined respiratory-tissue and immune-tissue bioregulator pairing, studied together for broader respiratory ageing and infection-resistance research aims.
- Chonluten + Cartalax → Research rationale: Both appear in the wider Khavinson tissue-specific bioregulator catalogue; referenced together in some Russian protocols examining combined connective and respiratory tissue ageing markers in older research subjects.
⚠️ Stack combinations listed for research reference only. Not safety or efficacy guidance.
Research Protocol Reference
experimental research protocols only — not dosing recommendations.
| Protocol |
Dose (experimental model only) |
Duration (experimental model only) |
Frequency (experimental model only) |
Research Context |
| Rodent Research Protocol |
Model-dependent, mcg/kg range reported in Russian literature |
10-20 days |
Once daily |
Bronchial epithelium and smoking-exposure marker studies in aged/exposed rodents. |
| Russian Small-Scale Human Study Protocol |
Reported in limited Russian clinical research settings; exact dosing not consistently published |
10-20 day course |
As per study protocol |
Reported in small Russian clinical research on respiratory tissue ageing markers; not independently replicated. |
Observed Side Effects in Research
- No significant adverse events reported in the available Khavinson-affiliated literature
- Independent Western safety data is not available
- Long-term human safety data does not exist outside limited Russian research settings
Because independent Western toxicology and safety studies have not been conducted, the absence of reported side effects in the existing literature should not be read as an established safety profile.
Compound Data
- CAS Number
- Not consistently assigned in Western chemical registries
- Molecular Formula
- C16H27N3O9 (approximate; Ala-Glu-Asp-Leu tetrapeptide)
- Molecular Weight
- Approximately 433.4 g/mol
- Half-Life
- Not established in independently published pharmacokinetic literature
- Synonyms
- Ala-Glu-Asp-Leu, AEDL peptide, bronchial epithelium bioregulator peptide
- Research Classification
- Khavinson-class short peptide bioregulator, tissue-specific (bronchial/lung epithelium) research peptide
Scientific References
The references below are drawn from Vladimir Khavinson's peptide bioregulator research programme. Readers should note this evidence base is almost entirely Russian preclinical and small-scale clinical research, published mainly in Russian-affiliated journals, and has not been replicated in Western randomised controlled trials. It should not be treated as equivalent in strength to Western RCT-based evidence.
- [Khavinson VK et al. 2012] — Peptide regulation of gene expression and protein synthesis in bronchial epithelium — Advances in Gerontology — [Animal / in vitro, Russian research programme]
- [Khavinson VK, Malinin VV] — Gerontological Aspects of Genome Peptide Regulation — Karger monograph — [Theoretical / mechanistic framework, tissue-specific bioregulator catalogue including Chonluten]
- [Khavinson VK et al.] — Short peptide bioregulators and markers of bronchial tissue ageing in smoking-exposure models — Bulletin of Experimental Biology and Medicine — [Animal / Russian research programme]
- [Umnov RS et al.] — Effects of tetrapeptide bioregulators on bronchial epithelial cell markers in vitro — Neuroscience and Behavioral Physiology — [In vitro]
*This compliance check is automated and does not constitute legal advice. No Nonsense Fitness recommends independent legal review for all published content.*